ClearNote Health’s Enhanced Avantect® Pancreatic Cancer Test Delivers Industry-Leading Early Detection Performance

Proprietary multianalyte and multiomic assay with optimized machine learning capabilities achieve significantly higher 82% sensitivity and 97% specificity in high-risk populations SAN DIEGO — Feb. 23, 2026 — ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced the availability of its enhanced Avantect® Pancreatic Cancer Test, which delivers significantly improved detection for patients at elevated risk of […] The post ClearNote Health’s Enhanced Avantect® Pancreatic Cancer Test Delivers Industry-Leading Early Detection Performance